Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter Phase 2 Study to Identify of the Optimal Neo-Adjuvant Combination Scheme of Ipilimumab and Nivolumab (OpACIN-neo)

NCT02977052 is registered in ClinicalTrials.gov with The Netherlands Cancer Institute as lead sponsor.

NCT NCT02977052
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02977052 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter Phase 2 Study to Identify of the Optimal Neo-Adjuvant Combination Scheme of Ipilimumab and Nivolumab (OpACIN-neo)
Lead sponsor
The Netherlands Cancer Institute
Phase
Phase 2
Overall status
Unknown status
Start date
November 24, 2016
Completion date
June 30, 2025
Enrollment
186 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

malignant melanoma stage iii